Abstract. In short QT syndrome, inherited gain-of-function mutations in the human ether a-gogo-related gene (hERG) K + channel have been associated with development of fatal arrhythmias. This implies that drugs that activate hERG as a side effect may likewise pose significant arrhythmia risk. hERG activators have been found to have diverse mechanisms of activation, which may reflect their distinct binding sites. Recently, the new hERG activator ICA-105574 was introduced, which disables inactivation of the hERG channel with very high potency. We explored characteristics of this new drug in several experimental models. Patch clamp experiments were used to verify activation of hERG channels by ICA-105574 in human embryonic kidney cells stablyexpressing hERG channels. ICA-105574 significantly shortened QT and QTc intervals and monophasic action potential duration (MAP 90 ) in Langendorff-perfused guinea-pig hearts. We also administered ICA-105574 to anesthetized dogs while recording ECG and drug plasma concentrations. ICA-105574 (10 mg/kg) significantly shortened QT and QTc intervals, with a free plasma concentration of approximately 1.7 μM at the point of maximal effect. Our data showed that unbound ICA-105574 caused QT shortening in dogs at concentrations comparable to the half maximal effective concentration (EC 50 , 0.42 μM) of hERG activation in the patch clamp studies.
Introduction
The rapid delayed rectifier K + channel current (I Kr ) conducted by the human ether a-go-go-related gene (hERG, now termed KCNH2) channel is a major contributor to repolarization of the cardiac action potential (1) . Loss-of-function mutations in hERG are associated with long QT syndrome (type LQT-2), which is a syndrome characterized by prolonged QT intervals on the electrocardiogram (ECG) and a ventricular tachycardia called torsades de pointes (TdP) (1, 2) . There is an acquired form of long QT syndrome typically caused by blockade of I Kr by commonly prescribed drugs, which can result in serious consequences including lethal arrhythmias and/or cardiac sudden death (3) . In contrast, little is known about the consequences of enhanced activation of the hERG channel, whether induced by genetic mutations or by pharmacological intervention. A form of inherited short QT syndrome (SQT-1) associated with a gain-of-function mutation in the hERG channel was first reported in 2004 (4) . At the cellular and tissue level, hERG activators have been employed to simulate SQT-1 and explore the cellular basis for its arrhythmogenesis. Based on structure-action-relationship analysis of hERG channels, previous hERG activators can be classified into at least two types. The drug RPR260243 binds to residues located near the intracellular end of the S5 and S6 transmembrane segments of the hERG channel and augments I Kr currents by a dual mechanism of slowed deactivation and attenuated P-type inactivation. Alternatively, PD-118057 binds to the pore helix and the nearby S6 segment and enhances I Kr currents by attenuating inactivation with little effect on deactivation.
Recently the organic chemical compound ICA-105574 was introduced as a new type of hERG activator (5) . Mutagenesis study (6) revealed that the molecular determinant of the binding site was distinct from those of RPR260243 and PD-118057, but had some overlap with them. ICA-105574 shifts the voltage dependence of Ptype inactivation to a very positive direction and removes the hERG channel from inactivation at physiological membrane potentials. Although the first report for ICA-105574 (5) showed shortening of action potential duration (APD) in guinea-pig ventricular myocytes, consequences of hERG activation by ICA-105574 in vivo have not been studied. Thus, the goal of the present study was to investigate the effects of ICA-105574 on ECG parameters and monophasic action potentials (MAP) obtained from Langendorff-perfused guinea-pig hearts and anesthetized dogs. In the canine experiments, free drug plasma concentrations were estimated from drug plasma concentrations.
Materials and Methods

Patch-clamp experiments
Patch-clamp experiments were conducted as described previously (7) . Briefly, human embryonic kidney (HEK) 293 cells stably expressing the hERG channel (Merck Millipore, Tokyo) were cultured in Minimum Essential Medium supplemented with 10% FBS and 0.5 mg/mL geneticine. hERG channel currents were recorded at room temperature (23°C -25°C) using the whole-cell patch clamp technique with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA). The control bath solution contained 137 mM NaCl, 4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, and 10 mM HEPES, pH 7.4. The drugs were added to the bath solution. Borosilicate glass pipettes (2 -5 MΩ resistance) were filled with an internal solution containing 130 mM KCl, 1 mM MgCl 2 , 5 mM EGTA, 5 mM MgATP, and 10 mM HEPES, pH 7.2. Series resistance was 3 -6 MΩ. Signals were filtered at 5 kHz, sampled at 10 kHz, and compensated for cell capacitance but not series resistance. Unless otherwise noted, hERG currents were elicited at 0.1 Hz with 2-s activating pulses to 10 mV (Vt) followed by 2-s pulses of −50 mV from a holding potential of −80 mV. To obtain concentration-response relationships, the peak current amplitudes at Vt were monitored until current magnitude reached a steady-state level before and after administration of drugs at each concentration. Clampex 9.2 or 10.1 software (Molecular Devices) was used to acquire and analyze data.
Animals
All experiments were performed according to the ''Rules for Feeding and Storage of Experimental Animals and Animal Experiments'' and approved by the Institutional Animal Care and Use Committee of Mitsubishi Tanabe Pharma Corporation.
ECG and MAP in Langendorff-perfused guinea-pig hearts
ECG and MAP were measured using the previously reported method (8) . Hearts were dissected from male Hartley guinea pigs (body weight 380 -650 g; Japan SLC, Inc., Shizuoka) anesthetized with sodium pentobarbital (50 mg/kg, i.p.; Kyoritsu Seiyaku Co., Tokyo), mounted on a Langendorff apparatus and perfused at approximately 80 mmHg with an aerated Krebs-Henseleit solution. Experiments were carried out with solution temperatures at 37°C ± 0.5°C. Two electrodes were placed, one at the apex of the heart and the other in the aortic cannula, to generate bipolar ECG. MAP was recorded from the epicardium of the left ventricular surface. The right ventricle was paced at approximately 2.5 times the threshold voltage by an electronic stimulator (Fukuda Denshi, Tokyo) via a bipolar electrode attached to its surface. Signals were amplified with differential amplifiers (DAM50 system; World Precision Instruments, Sarasota, FL, USA) and sampled at 1 kHz. Data were acquired and analyzed with WinVAS3 software (Ver. ] (11). In MAP recordings, the APD at the 90% repolarization level was defined as MAP 90 . To stabilize sinus rhythm beating, hearts were perfused for more than 60 min before experimental protocols were started. The evaluation protocol consisted of 20-min perfusion of vehicle [0.1% (v/v) dimethylsulphoxide, DMSO] as the control, followed by cumulative additions of ICA-105574 at final concentrations of 0.3, 1, and 3 μM (20-min perfusion for each). A vehicle only protocol was also run as a time-matched control. Parameters of ECG and MAP were evaluated at the end of each 20-min perfusion. In addition, MAP 90 was determined under pacing at 300 beats/min (bpm), a rate far above the spontaneous sinus rate. The pacing was also applied at the end of each 20-min perfusion period.
ECG recordings in anesthetized dogs
Surface lead II ECG was measured in four anesthetized male beagles (body weight, 11 -17 kg) as described previously (12) . The dogs were anesthetized initially with 30 mg/kg sodium thiopental, i.v. (Mitsubishi Tanabe Pharma, Osaka) and maintained in the anesthetized condition with inhalation of 1% halothane (Takeda Chemical Industries, Osaka). The ECG data were acquired with a polygraph system (RM-6000; Nihon Kohden, Tokyo) and recorded on graph paper as well as onto a computer at 1 kHz. Data analysis was performed with software WinVAS3 Ver1.1 (Physio-Tech, Tokyo) or manually using calipers. The ECG parameters studied were spontaneous heart rate, QRS duration, PR, QT, and QTc intervals. ICA was administered at two doses, 1 and 10 mg/kg, as a 10-min intravenous infusion every 30 min and compared with vehicle-only infusion. In two of the four dogs, a 3 mg/kg dose was studied as well. Each ECG parameter was evaluated before the start of infusion and at 5, 10, 15, 20, and 30 min after the start of infusion at each dose. In addition, at the highest dose of 10 mg/kg ICA-105547, ECG parameter evaluation was extended to include the time points 45 and 60 min after the start of the infusion.
Analytic determination of drug exposure
Plasma concentration of the drug was determined in the plasma samples obtained from the same animal in which surface ECG was monitored. Blood was sampled from the femoral vein at 5, 10, 20, and 30 min after the start of drug infusion and additionally at 60 min for the highest dose. The plasma was collected from the supernatant of blood samples except for the vehicle sample after centrifugation at 1500 g for 30 min at 4°C and stored at −80°C until the drug concentration was measured. Plasma concentration of ICA-105574 was determined by HPLC (Agilent 1200, Agilent Technologies or CLASS-VP, Shimadzu, Kyoto) and MS/MS (API 3000 or API 5000; AB SCIEX, Foster City, CA, USA). The protein binding ratio of ICA-105574 in canine plasma was determined by a micro-scale ultracentrifugation method (13) using UPLC/MS/MS (Waters, Milford, MA, USA). Estimated free drug plasma concentrations were calculated using the results of the protein binding ratio (98.8%).
Statistics
All values are presented as the mean ± S.E.M. Graphical and statistical analysis were carried out using Origin 8.0J (Microcal, Northampton, MA, USA) or SAS (SAS 9.1.3, SAS Institute, Cary, NC, USA), respectively. Statistical significance was assessed with Student's t-test for paired comparisons and adjusted by a Bonferroni method for multiple comparisons, unless otherwise noted. Time-dependent effects of ICA were analyzed in each group using one-way repeated measures ANOVA with the time as the factor of the analysis, followed by a Bonferroni post hoc test. Differences with P value < 0.05 were considered to be significant. Figure 1 confirms that ICA-105574 synthesized by us activated hERG currents as described previously (5). ICA-105574 enhanced the hERG currents during test pulses to 10 mV in a concentration-dependent manner. The EC 50 value was estimated as 0.42 ± 0.04 μM with a Hill coefficient (n H ) of 2.5 ± 0.3. The maximal increase in current amplitude (E max ) for ICA-105574 was 5.5 ± 0.3-fold greater than the control current. ICA-105574 had little effect on the peak tail currents at −50 mV (Fig.  1A) and at −120 mV (Fig. 1B) , and it slowed deactivation as described previously (5) .
Results
ICA-105574 increased hERG currents during the depolarization step
Analysis of the I-V relationship (Fig. 1B) showed that ICA-105574 enhanced peak hERG currents at test voltages (Vt) more positive than −50 mV (5). Under control conditions, the I-V relationships produced a bell-shape curve (maximal at 0 mV) which reflects the inward rectification of hERG channels resulting from slow activation and fast inactivation (14, 15) . ICA-105574 at 2 μM significantly enhanced peak hERG currents at Vt greater than −50 mV and abolished the inward rectification, suggesting that the P-type inactivation was progressively shifted to positive potentials as previously reported (5) . As a result, the relative increase in peak currents induced by the activator was more significant at very positive Vt higher than 10 mV. This result implies that ICA-105574 enhances outward cationic currents during the plateau phase of the action potential, resulting in acceleration of ventricular repolarization and shortening of APD.
QT shortening effects of ICA-105574 in guinea pigs
We tested whether ICA-105574 affected ECG and MAP in guinea-pig Langendorff hearts (Fig. 2) . ECG or MAP parameters obtained from the Langendorff hearts were stable during vehicle control (0.1% DMSO) perfusion throughout the experiment for more than 80 min. As shown in Fig. 2, at 3 μM, but not at 0.3 or 1 μM, ICA-105574 significantly shortened both QT and QTc (F) intervals and QTc (B) and QTc (V) intervals were as well (data not shown). In addition, MAP 90 recorded at 300 bpm was also shortened by application of 3 μM ICA- 
Effects of ICA-105574 on ECG parameters in anesthetized dogs
To test in vivo effects, we next examined the effects of ICA-105574 on the surface ECG in anesthetized dogs. Typical traces of lead II ECG are shown in Fig. 3A , and the time course of changes in the ECG parameters are plotted in Fig. 3B . Values of ECG parameters are summarized in Table 1 . The administration of 1 mg/kg ICA-105574 had no effect on ECG parameters except for an increase in heart rate by 18% of the pre-treatment control (n = 4, P < 0.05), similar to that caused by the vehicle (17%, n = 2), probably due to effects of the solvent. Administration of the drug at 3 mg/kg (n = 2) or 1 mg/kg (n = 2) produced no changes. Administration of 10 mg/ kg ICA-105574 significantly shortened QT and QTc (V), with a maximal change at 10-min after the start of drug infusion, and significantly increased heart rate by 55% of the pre-treatment control (n = 4, mean from 83 to 121 bpm, P < 0.01). The heart rate recorded at 10 mg/kg was higher than that of vehicle (by 17%), indicating that ICA-105574 affected the heart rate at this dose. After infusion of 10 mg/kg ICA-105574 for 5 -20 min, QTc (V) intervals were maximally shortened by 20% relative to the pre-treatment control, respectively (P < 0.01). QTc (B) and QTc (F) intervals were changed as well as QTc (V) (data not shown).
Drug concentration in plasma
The time courses of free plasma concentrations of ICA-105574 are summarized in Fig. 4 . The peaks of free drug plasma concentrations were observed at 10-min after the start of infusion (1 mg/kg: 0.16 ± 0.02 μM, n = 4; 3 mg/kg: 0.46 μM, n = 2; and 10 mg/kg: 1.67 ± 0.23 μM, n = 4), corresponding to the time of maximal changes in ECG parameters (Fig. 3) .
Discussion
The major finding of this work is that intravenous administration of the novel hERG activator ICA-105574 significantly shortens rate-corrected QT intervals and moderately increases heart rates in anesthetized dogs. This has a major impact on understanding of in vivo effects of hERG activators on cardiac electrophysiology.
A variety of drugs has been reported to cause acquired long QT syndrome through inhibition of the hERG channel. The non-clinical guidance detailed in the International Conference on Harmonization (ICH), S7B suggests that the potential of compounds to interact with I Kr (hERG) and to prolong the QT interval in non-rodent species should be evaluated prior to clinical trials. Compared with the enormous amount of accumulated knowledge on hERG blockers (16) , information on the in vivo effects of hERG activators is limited.
At cellular levels, it has been reported that there are at least two types of hERG activators (17) . The type 1 activator RPR260243 induces delayed deactivation and a positive shift in the voltage-dependence of inactivation (18, 19) . In type 2, PD-118057 (20) , its analogue PD-307243 (21), NS1643 (22, 23) , and A935142 (24) act primarily to attenuate inactivation. ICA-105574, the drug used in the current study, was initially classified as a type 2 drug because it exhibits a robust depolarizing shift in the voltage dependence of inactivation with modest changes in activation and deactivation (5, 6) . Recently, a site-directed mutagenesis study (6) revealed that the binding site on hERG channels for ICA-105574 was distinct from those of RPR260243 (type 1) and PD-118057 (type 2), suggesting that ICA-105574 could be classified as a third type of hERG activator. The binding site for ICA-105574 has overlap with the binding sites of the other two types of activators and with common inhibitors (Y652). Thus, the underlying effects on hERG are expected to vary between classes and between drugs within classes (25) .
Selective hERG inhibitors act to delay repolarization and prolong QT intervals on the ECG in vivo at free plasma concentrations comparable to hERG IC 50 . However, effective potential in vivo is not always comparable to in vitro efficacy for off-target drugs, which have effects on autonomic nervous systems or multiple channels or metabolism, or have indirect effects on the hERG channel such as block of trafficking (16, 26, 27) . In the in vivo experiments (Fig. 3) , ICA-105574 at a high dose (10 mg/kg) increased heart rates and shortened PR intervals, while ICA-105574 did not affect heart rates and PR intervals in excised Langendorff hearts (Fig. 2) . Thus, the autonomic nervous system might be involved in the effects on heart rates and PR intervals possibly by affecting blood pressure (no data). Furthermore, plasma protein binding may affect the effective dose by limiting effective exposure in vivo and should be considered when discussing the correlation between in vitro and in vivo studies. There is little information on this correlation for hERG activators. In the current study, we showed that ICA-105574 shortened QT and QTc intervals in vivo at similar concentrations to which ICA-105574 activates hERG currents in vitro, suggesting that ICA-105574 is selective for the hERG channel. To our knowledge, this is the first report to show in vivo effects of an hERGactivating compound against validated drug plasma concentrations. The reason that we used anesthetized animals in this study was that stable ECG was obtained continuously under controlled with drug plasma concentrations compared with conscious animals. The halothane probably reduces repolarization reserve through suppression of a slow component of delay rectifiers and the halothane anesthetized dog model has an extent of repolarization thought to be similar to that in healthy human volunteers (28) .
As some investigators argued (5), QT shortening by ICA-105574-induced hERG activation might have an impact on the treatment of cardiac arrhythmias associated with long QT intervals, suggesting a potential therapeutic utility of ICA-105574. However, as with the long QT syndromes, the fact that congenital short QT syndromes (29, 30 ) may lead to susceptibility to arrhythmias raises concerns that QT-shortening drugs could also lead to arrhythmic risk. Although non-clinical data have shown that drug-induced QT and QTc shortening can theoretically lead to ventricular fibrillation and sudden death, the clinical impact of short QT interval is still a matter of debate. The profibrillatory mechanism for short QT is still unclear, although one can speculate that QT shortening causes heterogeneity of repolarization in the heart. Therefore, we have to be careful to use an hERG-channel activator in any patients with electrophysiological disturbances. This study provides an animal model of druginduced QT shortening caused by hERG activation.
Limitations
Compound solubility issues and the multiple effects of the compound we studied made it more difficult to understand the effects of pure hERG activators in the whole heart. Therefore, the results were not sufficient to assess our hERG activator's potential for pro-arrhythmia. As a future direction, additional pro-arrhythmic intervention such as extra-pacing or sympathetic nervous stimulations may help to provide evidence for whether hERG activators such as ICA-105574 are pro-arrhythmic or antiarrhythmic. Because analyzing cardiac dispersion sometimes helps to understand the mechanisms of proarrhythmic effects, the data obtained from larger animals, such like dogs in this study, may help provide clues for novel mechanisms. 
